{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107389","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.004476+00:00","generated_at":"2026-05-16T23:23:32.225991+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Collegium Q3 revenue $209.4M (+31% YoY); raises 2025 guidance","bullets":["GAAP net income $31.5M ($0.84 diluted EPS); adj. net income $87.3M ($2.25 adj. EPS).","Record Jornay PM revenue $41.8M; prescriptions up 20% YoY; pain portfolio $167.6M (+11%).","Full-year 2025 revenue guidance raised to $775-785M; adj. EBITDA guidance $460-470M.","Ended Q3 with $285.9M cash; Board authorized $150M share repurchase through Dec 2026.","Adjusted EBITDA $133.0M, up 27% YoY; generated $78.4M cash from operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107389","json":"https://secwatch.observer/filing/0001104659-25-107389.json","markdown":"https://secwatch.observer/filing/0001104659-25-107389.md","text":"https://secwatch.observer/filing/0001104659-25-107389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925107389/0001104659-25-107389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000110465925107389/coll-20251106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:23:32.225991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}